Hepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate? Authors: Ubiratan Cassano-Santos, Eduardo Sica, Renata M Perez, Guilherme FM Rezende Published: 2024 To the editor, We read with enthusiasm the large cohort study of Halliday et al, 1 highlighting the prevalence of liver disease and portal hypertension (PH) in patients with common variable immunodeficiency (CVID), as well as their relationship with prognosis. At a time when the concept and recognition of porto-sinusoidal vascular disorder (PSVD) is expanding, it is essential to identify and better understand CVID, one of its associated conditions. An interesting aspect was the pulmonary involvement in 67.6% of the patients, significantly higher in those with liver disease (78% vs. 59.5%, p = 0.005). Considering the high prevalence of PH, 18.3% of the total sample and 43.9% in the group of patients with liver disease, 1 we speculated that some of these patients may have hepatopulmonary syndrome (HPS), a condition related to PH and often undiagnosed. Interestingly, the investigation of lung disease was made using chest CT and lung function tests, which may not identify HPS, increasing the chances that this condition has been underdiagnosed. Although the pathophysiology of PH associated with CVID is not completely established, nodular regenerative hyperplasia (NRH), a PSVD-defining condition whose pathogenesis is apparently related to blood flow abnormalities in the portal microvasculature, is frequently observed in liver biopsy. 2 Possible mechanisms related to vascular injury include endothelitis mediated by CD8 T lymphocytes. 1 Furthermore, bacterial translocation and the consequent production of endotoxins contribute to the worsening of PH and the emergence of complications such as HPS, similar to the “gut-liver axis” interaction observed in liver cirrhosis. The prevalence of HPS in the very heterogeneous population of patients with PSVD is still unknown; this association appears to be more frequent when PSVD occurs in the context of CVID, a condition in which the finding of NRH on biopsy is frequent. In fact, in a series of 19 patients with CVID associated with liver disease who underwent liver transplantation, it was observed that 8 patients (42%) had NRH at explant, half of them diagnosed with HPS. 3 Moreover, the comparison between the histopathological and hemodynamic findings of 96 patients with PSVD due to different causes demonstrated that the presence of NRH on liver biopsy was associated with higher levels of HVPG and that patients with HVPG ≥10 mm Hg had lower liver transplant–free survival compared to those with lower HVPG. 4 These data suggest that NRH is associated with more severe forms of PSVD, precisely when a higher prevalence of HPS would be expected. In conclusion, we believe that patients with PSVD associated with CVID benefit from further investigation of HPS, especially in those with established lung disease and NRH. Identification of HPS would guide treatment for this syndrome, which may be especially useful when therapy aimed exclusively at interstitial lung disease yields suboptimal results. In addition, earlier identification of potential candidates for liver transplantation due to HPS would avoid worse outcomes before progression to the very severe stage. 5 More studies are needed to establish the prevalence of HPS in PSVD. Acknowledgments CONFLICTS OF INTEREST The authors have no conflicts to report. Footnotes Abbreviations: CVID, common variable immunodeficiency; HPS, hepatopulmonary syndrome; NRH, nodular regenerative hyperplasia; PH, portal hypertension; PSVD, porto-sinusoidal vascular disorder. Contributor Information Ubiratan Cassano-Santos, Email: biracassano@yahoo.com.br. Eduardo Sica, Email: eduardosicap@gmail.com. Renata M. Perez, Email: renatamperez@gmail.com. Guilherme F.M. Rezende, Email: guimottarezende@gmail.com. REFERENCES